^
    Back
    Association details:
    Biomarker:DDX5 overexpression
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug:FL118 (DDX5 degrader)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASCO 2020
    Title:

    Sensitivity of colorectal or pancreatic cancers with high DDX5 and mutations in Kras and p53 genes to FL118 treatment.

    Published date:
    05/28/2020
    Excerpt:
    High expression of DDX5 (also called p68), a multifunctional oncogenic transcriptional co-activator and a DEAD-box RNA helicase, is associated with high FL118 efficacy in both CRC and PDAC PDX tumors….DDX5, mKras and mp53 appears to be favorable biomarkers for predicting FL118 high efficacy.
    DOI:
    10.1200/JCO.2020.38.15_suppl.e16102
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Clin Transl Med
    Title:

    FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy

    Excerpt:
    Our human tumour animal model studies further indicated that FL118 exhibits high efficacy to eliminate human PDAC and CRC tumours that have a high expression of DDX5...
    DOI:
    10.1002/ctm2.881